Posted by Michael Wonder on 05 Oct 2021
Adjuvant treatment for NSCLC: osimertinib mesylate may benefit certain people
1 October 2021 - Hint of considerable additional benefit if, after complete tumour resection, adjuvant platinum-based chemotherapy has already been carried out or is not suitable.
Osimertinib mesylate was the first medicine approved for adjuvant treatment after complete tumour resection in adults with non-small-cell lung cancer in stages IB to IIIA.
